Dolutegravir is one of the most potent antiviral drugs now being used in clinical practise to treat HIV. Scientists from the Salk Institute and the National Institutes of Health have discovered the molecular routes through which the human immunodeficiency virus (HIV) develops resistance to i
Researchers from the Salk Institute and the National Institutes of Health have identified the molecular pathways by which the human immunodeficiency virus (HIV) develops resistance to dolutegravir, one of the most potent antiviral medications now being used in clinical use to treat HIV.
Researchers from the Salk Institute and the National Institutes of Health have identified the molecular pathways by which the human immunodeficiency virus (HIV) develops resistance to dolutegravir, one of the most potent antiviral medications now being used in clinical use to treat HIV.
New Delhi [India], Dec 1 (ANI): The Union Health Ministry has planned to introduce a new drug for the treatment of patients suffering from HIV/AIDS. 'Dolutegravir' is a new drug which is likely to be available in the market by February 2020.